Study Evaluating Gefitinib (IRESSA®) in Subjects with Solid Malignancies that are Locally Advanced, Recurrent or Metastatic - AGUS
Study identifier:D7913C00022
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Open-Label, Dose Escalation Study Evaluating High-Dose Gefitinib (IRESSA®) on Weekly and Twice Weekly Schedules in Subjects with Solid Malignancies that are Locally Advanced, Recurrent or Metastatic
Medical condition
Tumors
Phase
Phase 1
Healthy volunteers
No
Study drug
Gefitinib
Sex
All
Actual Enrollment
66
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Jul 2005
Primary Completion Date: -
Study Completion Date: 01 Jan 2008
Study design
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Gefitinib (IRESSA®) | Drug: Gefitinib Oral tablet Other Name: IRESSA® |
